for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evolva Holding SA

EVE.S

Latest Trade

0.20CHF

Change

-0.00(-0.50%)

Volume

304,701

Today's Range

0.20

 - 

0.20

52 Week Range

0.20

 - 

0.37

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
0.20
Open
0.20
Volume
304,701
3M AVG Volume
45.05
Today's High
0.20
Today's Low
0.20
52 Week High
0.37
52 Week Low
0.20
Shares Out (MIL)
911.73
Market Cap (MIL)
185.38
Forward P/E
-6.78
Dividend (Yield %)
--

Latest Developments

More

Evolva Appoints Carsten Däweritz As CFO

Evolva Says CFO Leaves For Personal Reasons

Evolva Turns To FY Gross Loss Of CHF 1.9 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evolva Holding SA

Evolva Holding SA (Evolva) is a Switzerland-based biotechnology company reseaching, developing and commerzializing nature-based ingrendients. The activity of the Company is divided into two segments: technololgy platforms - combines biology with technology to produce nature-based ingredients; technology servises- provides tailored services to clients across industries. The Company is focused on developing and increase the yield and efficiency of the production of various ingredients.

Industry

Business Services

Contact Info

Duggingerstrasse 23

4153

Switzerland

+41.61.4852000

https://www.evolva.com/

Executive Leadership

Oliver Walker

Chief Executive Officer

Andre Pennartz

Chief Financial Officer

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (CHF)

2018

-0.038

2019

-0.030

2020

-0.040

2021(E)

-0.030
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.58
Price To Book (MRQ)
1.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.22
LT Debt To Equity (MRQ)
2.88
Return on Investment (TTM)
-18.02
Return on Equity (TTM)
-16.64

Latest News

Latest News

BRIEF-Evolva Holding 15-Day Public Review Period For Nootkatone Started In The U.S.

* UPON COMPLETION OF PUBLIC NOTICE PERIOD, COMPANY EXPECTS EPA TO COMPLETE REGISTRATION OF NOOTKATONE QUICKLY THEREAFTER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Evolva Signs CHF 12 Million Investment With Nice & Green

* SIGNS A CHF 12 MILLION INVESTMENT WITH SWISS COMPANY NICE & GREEN TO FUND FUTURE GROWTH

BRIEF-Evolva Holding Says Standby Equity Distribution Agreement Entered With Yorkville Advisors Will Expire On April 1

* EVOLVA HOLDING SA - STANDBY EQUITY DISTRIBUTION AGREEMENT ENTERED INTO IN 2017 WITH YORKVILLE ADVISORS WILL EXPIRE ON APRIL 1, 2020 Source text for Eikon: Further company coverage:

BRIEF-Evolva Says Enters New Agreement With International Flavors & Fragrances

* EVOLVA - ENTERS NEW AGREEMENT WITH INTERNATIONAL FLAVORS & FRAGRANCES

BRIEF-Evolva To Create Authorized Capital At Maximum Of CHF 32,875,129.40

* PROPOSES TO CREATE AUTHORIZED CAPITAL IN AMOUNT OF A MAXIMUM OF CHF 32,875,129.40

BRIEF-Evolva FY EBITDA At CHF -12.3 Mln

* FULL YEAR REVENUE INCREASED TO CHF 11.6 MILLION IN 2019 (+30%) MAINLY DRIVEN BY PRODUCT-RELATED REVENUES GROWING BY 59% TO CHF 5.5 MILLION

BRIEF-Evolva Announces Changes To Board Of Directors

* ANNOUNCES CHANGES TO BOARD OF DIRECTORS AND MANAGEMENT TEAM TO SUPPORT DELIVERY OF STRATEGIC PRIORITIES

BRIEF-Evolva: Board Of Directors Proposes Beat In-Albon As New Chairman

* EVOLVA WILL PROPOSE TO REDUCE OVERALL NUMBER OF BOARD MEMBERS FROM FIVE TO FOUR AT NEXT ANNUAL GENERAL MEETING Source text: https://bit.ly/2XRCnNu Further company coverage: (Gdansk Newsroom)

BRIEF-Evolva H1 Product Revenues Up At 3.0 Million Francs

* PRODUCT REVENUES REACHED CHF 3.0 MILLION IN FIRST HALF OF 2019 (+65%)

BRIEF-Evolva Holding: Stuart Strathdee To Retire From Board Of Directors

* STUART STRATHDEE TO RETIRE FROM BOARD OF DIRECTORS OF EVOLVA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Evolva Receives Notice From US EPA On Its Next-Generation Active Ingredient Against Ticks And Mosquitoes

* EVOLVA RECEIVES A NOTICE FROM US EPA ON ITS NEXT-GENERATION ACTIVE INGREDIENT AGAINST TICKS AND MOSQUITOES

BRIEF-Evolva Holding On Track To Reach Cash Break-Even In 2021/23 Timeframe

* CASH POSITION OF CHF 60.4 MILLION ON 31 DECEMBER 2018 (31 DECEMBER 2017: CHF 97.2M) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Evolva Holding Sees FY Product Sales Grow At High Double Digit Pct Rate

* FOR FULL YEAR 2018, WE EXPECT PRODUCT SALES TO GROW AT A HIGH DOUBLE DIGIT PERCENTAGE RATE.

BRIEF-Evolva Holding H1 Net Loss Narrows To CHF 14.7 Million

* PRODUCT SALES DOUBLED, REACHING CHF 1.8 MILLION IN THE FIRST HALF OF 2018

BRIEF-Evolva: Oliver Walker To Succeed Simon Waddington As CEO

* EVOLVA ANNOUNCES OLIVER WALKER TO SUCCEED SIMON WADDINGTON AS CEO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up